SCHEMBL6097264

SCHEMBL6097264

[CH2]Cc1ccc(-n2nc(C(C)(C)C)c(-c3ccccc3)c2C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
ATM Q13315 1/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
ALDH1A1 P00352 4/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095952 0.88 POLB (0.44) CYP1A2SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL6095734 0.85 CYP1A2 (0.38) CYP1A2ATMSMN1; SMN2NPC1RAB9A
SCHEMBL6097575 0.83 CYP1A2 (0.56) CYP1A2SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL6171466 0.76 HSD11B1 (0.42) CYP1A2SMN1; SMN2NPC1RAB9A
SCHEMBL6096303 0.73 CYP1A2 (0.45) CYP1A2SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL6098136 0.73 CYP2C19 (0.42) CYP1A2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL6098508 0.73 POLB (0.53) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL6095453 0.72 CYP1A2 (0.59) CYP1A2SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL23401126 0.71 MAPK14 (0.43) ATMSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL6097998 0.71 CYP1A2 (0.51) CYP1A2SMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001917-B2 Pyrazole compounds as anti-inflammatory and analgesic agents WARNER LAMBERT COMPANY LLC (US) 2006-02-21 US disclosed
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents HIRANO MISATO (JP) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents PTGER1, PTGS1, PTGIR CYP1A2 670/4885ATM 4261/4885SMN1; SMN2 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.